583 related articles for article (PubMed ID: 14625260)
41. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer.
Kerlikowske K; Barclay J; Grady D; Sickles EA; Ernster V
J Natl Cancer Inst; 1997 Jan; 89(1):76-82. PubMed ID: 8978410
[TBL] [Abstract][Full Text] [Related]
42. Factors Associated With Positive Margins in Women Undergoing Breast Conservation Surgery.
Murphy BL; Boughey JC; Keeney MG; Glasgow AE; Racz JM; Keeney GL; Habermann EB
Mayo Clin Proc; 2018 Apr; 93(4):429-435. PubMed ID: 29439832
[TBL] [Abstract][Full Text] [Related]
43. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
44. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L
Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102
[TBL] [Abstract][Full Text] [Related]
45. Ductal carcinoma in situ: size and resection volume predict margin status.
Melstrom LG; Melstrom KA; Wang EC; Pilewskie M; Winchester DJ
Am J Clin Oncol; 2010 Oct; 33(5):438-42. PubMed ID: 20023569
[TBL] [Abstract][Full Text] [Related]
46. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.
Bijker N; Peterse JL; Duchateau L; Julien JP; Fentiman IS; Duval C; Di Palma S; Simony-Lafontaine J; de Mascarel I; van de Vijver MJ
J Clin Oncol; 2001 Apr; 19(8):2263-71. PubMed ID: 11304780
[TBL] [Abstract][Full Text] [Related]
47. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
Worni M; Akushevich I; Greenup R; Sarma D; Ryser MD; Myers ER; Hwang ES
J Natl Cancer Inst; 2015 Dec; 107(12):djv263. PubMed ID: 26424776
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials.
Garg PK; Jakhetiya A; Pandey R; Chishi N; Pandey D
Breast J; 2018 May; 24(3):233-239. PubMed ID: 28833776
[TBL] [Abstract][Full Text] [Related]
50. Twenty-year outcomes after breast-conserving surgery and definitive radiotherapy for mammographically detected ductal carcinoma in situ.
Wilkinson JB; Vicini FA; Shah C; Shaitelman S; Jawad MS; Ye H; Kestin LL; Goldstein NS; Martinez AA; Benitez P; Chen PY
Ann Surg Oncol; 2012 Nov; 19(12):3785-91. PubMed ID: 22644510
[TBL] [Abstract][Full Text] [Related]
51. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy.
White J; Levine A; Gustafson G; Wimbish K; Ingold J; Pettinga J; Matter R; Martinez A; Vicini F
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):791-7. PubMed ID: 7860390
[TBL] [Abstract][Full Text] [Related]
52. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
Sanders ME; Schuyler PA; Dupont WD; Page DL
Cancer; 2005 Jun; 103(12):2481-4. PubMed ID: 15884091
[TBL] [Abstract][Full Text] [Related]
53. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
54. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials.
Viani GA; Stefano EJ; Afonso SL; De Fendi LI; Soares FV; Leon PG; Guimarães FS
Radiat Oncol; 2007 Aug; 2():28. PubMed ID: 17683529
[TBL] [Abstract][Full Text] [Related]
55. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.
McCormick B; Winter K; Hudis C; Kuerer HM; Rakovitch E; Smith BL; Sneige N; Moughan J; Shah A; Germain I; Hartford AC; Rashtian A; Walker EM; Yuen A; Strom EA; Wilcox JL; Vallow LA; Small W; Pu AT; Kerlin K; White J
J Clin Oncol; 2015 Mar; 33(7):709-15. PubMed ID: 25605856
[TBL] [Abstract][Full Text] [Related]
56. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence.
Rauch GM; Hobbs BP; Kuerer HM; Scoggins ME; Benveniste AP; Park YM; Caudle AS; Fox PS; Smith BD; Adrada BE; Krishnamurthy S; Yang WT
Ann Surg Oncol; 2016 Feb; 23(2):482-9. PubMed ID: 26416712
[TBL] [Abstract][Full Text] [Related]
57. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
[TBL] [Abstract][Full Text] [Related]
58. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
59. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
60. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
